Home » News » Markets » This Pharma Company Declares 400% Final Dividend, Finalises Record Date
3-MIN READ

This Pharma Company Declares 400% Final Dividend, Finalises Record Date

By: Aparna Deb

Last Updated: June 28, 2022, 11:33 IST

AstraZeneca Pharma has declared dividend for the fiscal year 2021–2022

AstraZeneca Pharma has declared dividend for the fiscal year 2021–2022

AstraZeneca Pharma India Ltd., a mid-cap company with a market cap of Rs. 6,822 crore, has declared dividend for the fiscal year 2021–2022

AstraZeneca Pharma Stock: AstraZeneca Pharma India Ltd., a mid-cap company with a market cap of Rs. 6,822 crore, has declared a dividend for the fiscal year 2021–2022. The company’s board has recommended a final dividend of Rs. 8–per equity share, or 400 per cent at face value of Rs 2. AstraZeneca Pharma has announced a 500.00 per cent dividend, or Rs. 10 per share, for the fiscal year ending March 2022. (earlier dividend Rs 2.00 in Q3). The dividend yield at the present share price of Rs 2,708 is 0.36 per cent.

For the purpose of dividend, today the company has announced the record date. AstraZeneca Pharma India has said in BSE filing that “Further to our intimation dated May 26, 2022, we wish to inform that the Record Date for determining the entitlement of the shareholders for the payment of the Final Dividend for financial year 2021-22 is July 8, 2022. The Final Dividend, if approved by the shareholders, shall be paid/dispatched to the shareholders on or before September 6, 2022.”

AstraZeneca India was established in 1979 and is headquartered in Bengaluru, Karnataka. AstraZeneca Pharma India Limited (AZPIL) is an operating company that covers the manufacturing, sales, and marketing activities of the company in India. It is a listed company and is a subsidiary of AstraZeneca Plc, UK. It has a workforce of over 1400 employees across the country that is committed to delivering life-changing medicines to patients through innovative science and global excellence in development and commercialization. With a global clientele, the firm works in key healthcare sectors like oncology, respiratory, cardiovascular, renal, and metabolic illnesses.

The company reported a two per cent rise in March quarter net profit at Rs 27.98 crore from the same quarter last year. Net revenue rose 10.3 per cent at Rs 232 crore. The company has had no debt for the last 5 years. 

Stock Price History

AstraZeneca’s share price was Rs 2,729.10 as of June 27, 2022, 03:49 PM IST. AstraZeneca’s share price was down by 0.22 per cent based on previous share price of Rs. 2933.2. In the last 1 Month, AstraZeneca’s share price moved down by 7.66 per cent. AstraZeneca’s share price saw a 52-week high of Rs 3,679.95 and 52 week low of Rs 2,445.70. The Stock gave a 3-year return of 28.19 per cent as compared to the Nifty Midcap 100 which gave a return of 49.28 per cent. (as of last trading session). Stock generated 28.19 per cent return as compared to Nifty Pharma which gave investors 50.57 per cent return over 3 year time period. (as of last trading session).

What Do Analysts Say?

Ravi Singh-Vice President and Head of Research-ShareIndia, said: “The stock has declined 12.11 per cent so far in 2022 as per year-to-date data and 25.84 per cent last year. The shares of AstraZeneca Pharma India are now trading 26.41 per cent below the 52-week high and 10.72 per cent above the 52-week low on the NSE, respectively. The stock reached a 52-week high of Rs 3,679.95 on June 24, 2021, and a 52-week low of Rs 2,445.70 on May 12, 2022. The stock may see some more selling pressure and touch the levels of Rs 2,550 in the near term. Investors must wait to lower levels for a value buying opportunity.”

Manoj Dalmia Founder and Director-Proficient Equities Limited said: “The stock is currently trading at 13 times its Book Value and is overvalued with a PE multiple of 109  compared to its peers, even the sales have seen just 8% CAGR growth over 5 yrs. Currently, investors can wait for Rs 1,900 levels to reach and accumulate, the stock is set to be volatile to sideways in the near term.”

The views and investment tips by experts in this News18.com report are their own and not those of the website or its management. Users are advised to check with certified experts before taking any investment decisions.

Read all the Latest News , Breaking News , watch Top Videos and Live TV here.

first published:June 28, 2022, 09:10 IST
last updated:June 28, 2022, 11:33 IST